​Launch Excellence V
​Surviving and thriving when launching in an increasingly specialised world
White Paper

The next decade will see greater concentration of competition for innovative Launches, with focus turning to more specialist therapy areas, limited key launch countries, healthcare budgets, doctor attention time, and even patients. Achieving true Launch Excellence will become even more challenging. To understand how to succeed in the future, companies must first understand how today’s launch environment drivers came to be.

Ten years ago, IMS Health (now IQVIA) published a white paper entitled “Launch Excellence”. It defined objective criteria for excellence in launch for prescription medicines and developed in-depth insight on medicines that achieved them. We drew tough but surprising conclusions. For example, that the first six months has a disproportionate influence on later success for at least 80% of launches in any country.

New Chemical Entity launch success is still, overwhelmingly, a developed markets game: 86% of the first five years’ sales of New Chemical Entities launches since 2005 came from just seven countries: the U.S., Japan, Germany, France, UK, Spain and Italy. Our interviews with companies preparing for launch suggest the overwhelming majority, if asked, will classify themselves as “behind” on some or all aspects of their launch preparation. But some of these companies will go on to have excellent launches — others will not. Quality of preparation matters as well as quantity.

A decade of launch excellence insight: What does it tell us about the future of the pharmaceutical industry?

Launch Excellence is at the heart of many of the fundamental changes in the pharmaceutical industry’s landscape. Launches drive pharmaceutical industry change, so excellence in launch is the key to the pharmaceutical industry’s future.

The first Launch Excellence white paper analysed launches back to 1995, an almost Jurassic era when the big beasts of the pharmaceutical launch world were primary care, mass market products: Lipitor, Plavix, Seretide, or Detrusitol.

 

Download to read more
RELATED SOLUTIONS
Track and execute successful new product launches

Use a web-based platform to identify crucial pre-launch activities, create and monitor launch plans across your entire global portfolio across different markets

Launch Planning and Management

Assess and enhance launch preparations. Optimize launch execution.

Launch Advisory Services

Launch with confidence and excellence the first time.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.